Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Few things have stirred up as much commotion in either the weight loss or pharmaceutical world as Ozempic and Wegovy ... of 14.9% of their body weight after 68 weeks, compared with an average ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback